PYC Stock Overview
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
PYC Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.25 |
| 52 Week High | AU$2.10 |
| 52 Week Low | AU$0.90 |
| Beta | 0.63 |
| 1 Month Change | 23.15% |
| 3 Month Change | -0.40% |
| 1 Year Change | 25.00% |
| 3 Year Change | 54.32% |
| 5 Year Change | 71.23% |
| Change since IPO | -51.92% |
Recent News & Updates
Recent updates
We're Hopeful That PYC Therapeutics (ASX:PYC) Will Use Its Cash Wisely
Oct 25
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Apr 10Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?
Nov 10We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully
Jul 03Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Jan 25Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth
Jul 31We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate
Mar 28Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)
Feb 20
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?
Jan 26What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition
Dec 22We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth
Nov 17The Independent Non-Executive Director of PYC Therapeutics Limited (ASX:PYC), Bernard Hockings, Just Sold 25% Of Their Holding
Jun 17Shareholder Returns
| PYC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 2.0% | -6.7% | 0.05% |
| 1Y | 25.0% | -10.4% | 4.3% |
Return vs Industry: PYC exceeded the Australian Biotechs industry which returned -10.4% over the past year.
Return vs Market: PYC exceeded the Australian Market which returned 4.3% over the past year.
Price Volatility
| PYC volatility | |
|---|---|
| PYC Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: PYC has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PYC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Rohan Hockings | pyctx.com |
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.
PYC Therapeutics Limited Fundamentals Summary
| PYC fundamental statistics | |
|---|---|
| Market cap | AU$688.68m |
| Earnings (TTM) | -AU$48.20m |
| Revenue (TTM) | AU$24.99m |
27.6x
P/S Ratio-14.3x
P/E RatioIs PYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PYC income statement (TTM) | |
|---|---|
| Revenue | AU$24.99m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$24.99m |
| Other Expenses | AU$73.19m |
| Earnings | -AU$48.20m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.087 |
| Gross Margin | 100.00% |
| Net Profit Margin | -192.90% |
| Debt/Equity Ratio | 0% |
How did PYC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/10 20:34 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PYC Therapeutics Limited is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| David Martin | Bloom Burton & Co. |